GUARD THERAPEUTICS INTERNATIONAL AB (PUBL)

(GUARD)
  Rapporto
Tempo differito Nasdaq Stockholm  -  17:29 12/08/2022
0.9500 SEK    0.00%
01/06Guard Therapeutics riceve l'approvazione dell'Agenzia svedese per i prodotti medici per condurre uno studio clinico su RMC-035 nel trapianto di rene.
CI
12/05Guard Therapeutics International AB (publ) riporta i risultati degli utili per il primo trimestre conclusosi il 31 marzo 2022
CI
26/04Guard Therapeutics International AB (publ) nomina Torbjörn Larsson capo del CMC (chimica, produzione e controlli), a partire dal 1 maggio 2022
CI
RiassuntoQuotazioniGraficiNotizieRatingCalendarioSocietąFinanzaConsensusRevisioniDerivati 
RiassuntoTutte le notizieAltre lingueComunicati stampaPubblicazioni ufficialiNotizie del settore
Notizie in altre lingue su GUARD THERAPEUTICS INTERNATIONAL AB (PUBL)
01/06Guard Therapeutics receives approval from the Swedish Medical Products Agency to conduc..
01/06Guard Therapeutics Receives Approval from the Swedish Medical Products Agency to Conduc..
28/05Certain Shares of Guard Therapeutics International AB are subject to a Lock-Up Agreemen..
12/05Guard Therapeutics International AB Reports Earnings Results for the First Quarter Ende..
26/04Guard Therapeutics recruits new Head of CMC
26/04Guard Therapeutics International AB Appoints Torbjörn Larsson as Head of CMC (Chemistry..
13/04Guard Therapeutics provides in-depth information on phase 2 clinical trial
13/04Guard Therapeutics International AB Provides In-Depth Information on Phase 2 Clinical T..
07/04First patient has been dosed in Guard Therapeutics' Phase 2 clinical trial of ROSgard
07/04Guard Therapeutics Announces First Patient Has Been Dosed in Guard Therapeutics' Phase ..
22/02Guard Therapeutics International AB Reports Earnings Results for the Fourth Quarter End..
22/02Guard Therapeutics International AB Reports Earnings Results for the Full Year Ended De..
12/01Guard Therapeutics receives approval to expand the global phase 2 study of ROSgard to C..
12/01Guard Therapeutics Receives Approval to Expand the Global Phase 2 Study of Rosgard to C..
05/01Guard Therapeutics' application to conduct a phase 2 clinical trial of ROSgard is appro..
05/01Guard Therapeutics’ Application to Conduct a Phase 2 Clinical Trial of ROSgard is ..
2021Guard Therapeutics appoints Michael Reusch as Chief Medical Officer
2021Guard Therapeutics Appoints Michael Reusch as Chief Medical Officer, Effective January ..
2021Guard Therapeutics announces final result of rights issue
2021Guard Therapeutics announces preliminary result of rights issue
2021Guard Therapeutics publishes supplementary prospectus
2021Guard Therapeutics reports positive results from preclinical studies
2021Guard Therapeutics International AB Reports Positive Results from Preclinical Studies
2021Guard Therapeutics publishes prospectus due to upcoming rights issue
2021Guard Therapeutics International AB Reports Earnings Results for the Third Quarter and ..
2021GUARD THERAPEUTICS INTERNATIONAL: carries out, subject to approval from the Extraordinary..
2021GUARD THERAPEUTICS INTERNATIONAL: intends to carry out a capital raise of approximately S..
2021GUARD THERAPEUTICS INTERNATIONAL: reports positive results from phase 1b study
2021Guard Therapeutics International AB Reports Positive Results from Phase 1B Study
2021GUARD THERAPEUTICS INTERNATIONAL: European Patent Office grants patent for Guard Therapeu..
2021Guard Therapeutics International AB Publ Reports Earnings Results for the Second Quarte..
2021GUARD THERAPEUTICS INTERNATIONAL: Last patient recruited to Guard Therapeutics' phase 1b ..
2021GUARD THERAPEUTICS INTERNATIONAL: establishes a scientific committee with prominent inter..
2021Guard Therapeutics International AB Publ Reports Earnings Results for the First Quarter..
2021GUARD THERAPEUTICS INTERNATIONAL: receives an Intention to Grant notice in Europe for ROS..
2021ERS TEST AG: Vorabbekanntmachung über die Veröffentlichung von Zahlungsberichten gemäß § ..
2021ERS TEST AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß § 11..
2021GUARD THERAPEUTICS INTERNATIONAL: obtains a granted patent from USPTO concerning ROSgard ..
2021GUARD THERAPEUTICS INTERNATIONAL: First patient dosed in Guard Therapeutics' phase 1b stu..
2021Guard Therapeutics International AB Reports Earnings Results for the Full Year Ended De..
2021GUARD THERAPEUTICS INTERNATIONAL: appoints Sara Thuresson as Head of Clinical Operations
2021Guard Therapeutics appoints Sara Thuresson as Head of Clinical Operations
2021GUARD THERAPEUTICS INTERNATIONAL: patent granted in Australia
2020GUARD THERAPEUTICS INTERNATIONAL: completes successful pre-IND meeting with FDA
2020Guard Therapeutics International AB Completes Pre-IND meeting with FDA
2020GUARD THERAPEUTICS INTERNATIONAL: appoints Ann-Kristin Myde as Head of Global Project Man..
2020Guard Therapeutics Appoints Ann-Kristin Myde as Head of Global Project Management, Effe..
2020GUARD THERAPEUTICS INTERNATIONAL: receives Notice of Allowance from USPTO for ROSgard
2020GUARD THERAPEUTICS INTERNATIONAL: - Overlooked Opportunity
2020GUARD THERAPEUTICS INTERNATIONAL: - Moving In the Right Direction
2020GUARD THERAPEUTICS INTERNATIONAL: reports positive top-line results from phase 1 study of..
2020Guard Therapeutics Reports Positive Top-Line Results from Phase 1 Study of Rosgard in I..
2020GUARD THERAPEUTICS INTERNATIONAL PUB: rapporterar positiva interimresultat från en fas 1-..
2020GUARD THERAPEUTICS INTERNATIONAL PUB: rapporterar positiva top line-resultat från den avs..
2020GUARD THERAPEUTICS INTERNATIONAL PUB: announces positive top line results from the conclu..
2020Guard Therapeutics Announces Positive Top Line Results from the Concluding Study in the..
2020GUARD THERAPEUTICS INTERNATIONAL PUB: presents positive follow-up analysis from phase 1 s..
2020GUARD THERAPEUTICS INTERNATIONAL PUB: appoints Peter Gilmour as Head of Preclinical Scien..
2020Guard Therapeutics Appoints Peter Gilmour as Head of Preclinical Science, Effective 1 A..
2020Guard Therapeutics International AB Announces Positive Top Line Results from Clinical P..
2019A1M Pharma AB will Change its Name to Guard Therapeutics International AB
2019A1M Pharma Announces Positive Top-Line Results from A Phase 1A Study of ROSgard
2019A1M Pharma AB announced that it expects to receive SEK 27.2 million in funding
2018Swedish Medical Products Agency Grants A1M Pharma Permission to Start a Clinical Phase ..
2018A1M Pharma re-submits application to the Swedish Medical Products Agency to conduct cli..
2018A1M Pharma AB to Prioritize the Indication Acute Kidney Injuries in Further Development..
2018A1M Pharma Appoints Tobias Larsson Agervald as Chief Medical Officer
2018A1M Pharma Reports Positive Results from Preclinical Study in Acute Kidney Injuries
2018A1M Pharma Collaborates with Antaros Medical to Study Harmful Effects During PRRT Radia..
2017A1M Pharma AB Reports Positive Results from its GLP Toxicology Study
2017A1M Pharma AB Manufactures A1M Under Full GMP Compliance for Clinical Studies
2016A1M Pharma to Use Experienced European CRO Partner for Preclinical Toxicology Studies
2016A1M Pharma Initiates Research Collaboration with CSL Behring for Combination Treatment ..
2015A1M Pharma Appoints Martin Austin as Business Development Director
2013A1M Pharma AB announced that it has received SEK 15 million in funding from Private Pla..
1  2Succ.
Prossimo evento su GUARD THERAPEUTICS INTERNATIONAL AB (PUBL)